Skip to main content

Drug Interactions between burosumab and Taclonex Scalp

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

calcipotriene topical burosumab

Applies to: Taclonex Scalp (betamethasone / calcipotriene topical) and burosumab

Consumer information for this interaction is not currently available.

CONTRAINDICATED: Concomitant use of burosumab with oral phosphate and/or active vitamin D analogs may increase the risk of hyperphosphatemia and hypervitaminosis D due to additive pharmacologic effects. Increases in serum phosphorus to above the upper limit of normal may be associated with an increased risk of nephrocalcinosis.

MANAGEMENT: Oral phosphate and active vitamin D analogs should be discontinued one week prior to initiation of burosumab treatment. Fasting serum phosphorus concentration should be below the reference range for age prior to initiation of treatment. Some authorities advise that, if necessary, vitamin D replacement or supplementation with inactive forms of vitamin D may be started or continued as per local guidelines and under serum calcium and phosphate monitoring.

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer